Crage Medical Co., Limited

Shanghai Cancer Institute

Carsgen Therapeutics Limited

Carsgen Therapeutics Co., Ltd.

Cafa Therapeutics Limited

Shanghai Yile Biotechnology Limited

Shanghai Yijie Biotechnology Co., Ltd

Zonghai Li

Huamao Wang

Hua Jiang

Peng Wang

Huiping Gao

Bizhi Shi

Jianren Gu

Shengli Yang

Min Zhou

Zhimin Shi

Hai Feng Wang

Hongyang Wang

Bo Song

Ruping Dai

Juan Kong

Linlin Yang

Xiaorong Pan

Xiuqi Wu

Hong Luo

Kesang Li

Zeyan Pan

Disclosed in the present invention is a genetically engineered cell, expressing an exogenous receptor that specifically binds to a target antigen and exogenous CCL21, and capable of further expressing an IL-7R binding protein or exogenous IL-7 that promotes cell proliferation. Also disclosed are an expression construct comprising an exogenous CCL21 expression cassette, and a vector containing same, a virus, and a pharmaceutical composition comprising said cell. Also disclosed is an application for the cell, the expression construct, the vector, and the virus in the preparation of drugs for inhibiting tumours or inhibiting pathogens.

Genetically engineered cell and application thereof

Provided in the present invention are a composition of immune effector cells and a treatment kit including the composition of immune effector cells, wherein the composition of immune effector cells comprises an initial dose of immune effector cells and a subsequent dose of immune effector cells.

Method and composition for treating tumors

Provided in the present invention is a method for treating tumor. An immune effector cell and a second treatment agent are applied to individual suffering from tumor, wherein the immune effector cell expresses a receptor for recognizing tumor antigen, and wherein the second treatment agent is a compound of formula I or a pharmaceutically acceptable salt thereof.

Combination of cellular immunotherapy

Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

Compositions and methods of cellular immunotherapy

A binding unit that specifically binds to fibroblast activation protein &#x3b1; (FAP&#x3b1;), a polynucleotide that encodes the binding unit, a vector that comprises the polynucleotide and a host cell, a method for use in producing the antigen-binding unit and a method for treating a disease by using the FAP&#x3b1;-specific binding unit; the binding unit that specifically binds to FAP&#x3b1; may efficiently bind to tumor cells that express FAP&#x3b1;, and immune effector cells comprising the binding unit exhibit significant killing capabilities against tumor cells that express FAP.

Binding unit targeting fibroblast activation protein &#x3b1; and application thereof

Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized antibody of the present invention not produce an anti-antibody response (AAR) and a human anti-mouse antibody response (HAMA), but same also has better affinity than a murine antibody, and has excellent activity and safety, thereby providing a new means for treating CD19-expressing tumors.

Anti-CD19 humanized antibody and immune effector cell targeting cd 19

Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.

Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agent

Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.

Antibody for anti-claudin 18A2 and use thereof

A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

Chimeric antigen receptors targeting GPC3 and uses thereof

A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287to 302amino acid epitopes of a human epidermal growth factor receptor (EGFR).

Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein

Multi-functional antibody polypeptide comprises:

Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigen

The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128amino acid in a specific recognition pro-BDNF precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains.

Anti-human proBDNF monoclonal antibody, and uses thereof in pains

The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.

Human epidermal growth factor receptor variant lacking an exon

Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

Growing community of inventors

Shanghai, China

Zonghai Li